Our study reveals differences in the clinical characteristics of patients with different molecular subtypes, with a higher proportion of women with TN status and HER-2+ having larger tumor size, advanced stage at diagnosis and lymph node metastasis. This evidence concerns the gene ERBB2 and neoplasm.